Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co. is engaged in developing and commercializing targeted therapies for patients with genomically-defined cancers. Co.'s main product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. Co.'s second product candidate, pimasertib, is an oral, highly-selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the RAS/mitogen-activated protein kinase pathway. The DAWN average annual return since 2021 is shown above.
The Average Annual Return on the DAWN average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether DAWN average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the DAWN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|